Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
- Wednesday, January 22, 2020, 7:20
- PR Newswire
- Add a comment
BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of…
About the Author
admin has written 21643 stories on this site.